BriaCell publishes investor presentation on Bria-IMT pivotal Phase 3 metastatic breast cancer program

• Briacell highlighted Bria-IMT as its lead program, with a pivotal Phase 3 trial underway in metastatic breast cancer with overall survival as primary endpoint.
• Phase 3 design targets an interim analysis at 144 events; BLA submission planned if hazard ratio is ≤0.6, otherwise trial continues targeting 0.7.
• Phase 2 Bria-IMT plus checkpoint inhibitor data showed median PFS 3.6 months for the selected Phase 3 formulation; comparable literature cited 1.6-2.5 months.
• Randomized Phase 2 overall survival was 13.3 months for the Phase 3 sequence; 16.6 months for the Phase 3 formulation and sequence.
• Bria-OTS platform programs advanced in breast cancer; next-generation Bria-BRES+ has an open IND with patient recruitment underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief on June 19, 2026, and is solely responsible for the information contained therein.